Targeting the N-cadherin/β-catenin axis with MSAB reverses malignant phenotypes in blast crisis of CML
Our findings elucidate the role of CDH2 in CML progression through activation of the Wnt/<i>β</i>-catenin signaling pathway. Targeting the N-cadherin/<i>β</i>-catenin axis with MSAB may represent a novel therapeutic strategy for BC-CML.
Authors
- Ruyi Qiu
- Xiaofang Li (ORCID: https://orcid.org/0000-0003-1554-4484)
- Yingying Zhou (ORCID: https://orcid.org/0000-0001-5533-097X)
- Lijun Lu (ORCID: https://orcid.org/0000-0001-5073-3753)
- Jian Shen (ORCID: https://orcid.org/0000-0003-1877-586X)
Institutions
- Zhejiang Provincial Hospital of TCM (CN)
- Hangzhou DAC Biotech (China) (CN)
- Taizhou First People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.3389/fonc.2025.1657508
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Taizhou Municipal Science and Technology Bureau
- Natural Science Foundation of Zhejiang Province